Search

Author/Creator Triebel, Frederic

1. 790 A phase II study (TACTI-002) of eftilagimod alpha (a soluble LAG-3 protein) with pembrolizumab in PD-L1 unselected patients with metastatic non-small cell lung(NSCLC) or head and neck carcinoma(HNSCC). (10th December 2020)

Authors:
Krebs, Matthew; Majem, Margarita; Felip, Enriqueta; Forster, Martin; Doger, Bernard; Clay, Tim; Carcereny, Enric; Peguero, Julio; Horn, Leora; Bajaj, Pawan; Roxburgh, Patricia; Brignone, Chrystelle; Mueller, Christian; Triebel, Frederic
Journal:
Journal for immunotherapy of cancer
Issue:
Volume 8(2020)Supplement 3
Page Start:
A472
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. 790 A phase II study (TACTI-002) of eftilagimod alpha (a soluble LAG-3 protein) with pembrolizumab in PD-L1 unselected patients with metastatic non-small cell lung(NSCLC) or head and neck carcinoma(HNSCC). (9th November 2020)

Authors:
Krebs, Matthew; Majem, Margarita; Felip, Enriqueta; Forster, Martin; Doger, Bernard; Clay, Tim; Carcereny, Enric; Peguero, Julio; Horn, Leora; Bajaj, Pawan; Roxburgh, Patricia; Brignone, Chrystelle; Mueller, Christian; Triebel, Frederic
Journal:
Journal for immunotherapy of cancer
Issue:
Volume 8(2020)Supplement 3
Page Start:
A839
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. New Cancer Immunotherapy Agents in Development: a report from an associated program of the 31stAnnual Meeting of the Society for Immunotherapy of Cancer, 2016. Issue 1 (20th June 2017)

Authors:
Adusumilli, Prasad S.; Cha, Edward; Cornfeld, Mark; Davis, Thomas; Diab, Adi; Dubensky, Thomas W.; Evans, Elizabeth; Grogan, Jane L.; Irving, Bryan A.; Leidner, Rom S.; Olwill, Shane A.; Soon-Shiong, Patrick; Triebel, Frederic; Tuck, David; Bot, Adrian; Dansey, Roger D.; Drake, Charles G.; Freema...
Journal:
Journal for immunotherapy of cancer
Issue:
Volume 5:Issue 1(2017)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. Eftilagimod alpha, a soluble lymphocyte activation gene-3 (LAG-3) protein plus pembrolizumab in patients with metastatic melanoma. Issue 2 (20th November 2020)

Authors:
Atkinson, Victoria; Khattak, Adnan; Haydon, Andrew; Eastgate, Melissa; Roy, Amitesh; Prithviraj, Prashanth; Mueller, Christian; Brignone, Chrystelle; Triebel, Frederic
Journal:
Journal for immunotherapy of cancer
Issue:
Volume 8:Issue 2(2020)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗